HUP9801384A2 - Klostridium perfringens vakcina - Google Patents

Klostridium perfringens vakcina

Info

Publication number
HUP9801384A2
HUP9801384A2 HU9801384A HUP9801384A HUP9801384A2 HU P9801384 A2 HUP9801384 A2 HU P9801384A2 HU 9801384 A HU9801384 A HU 9801384A HU P9801384 A HUP9801384 A HU P9801384A HU P9801384 A2 HUP9801384 A2 HU P9801384A2
Authority
HU
Hungary
Prior art keywords
toxin
subject
cells
well
expression systems
Prior art date
Application number
HU9801384A
Other languages
English (en)
Inventor
Peer Lyng Frandsen
Ruund Philip Antoon Maria Segers
Nicolas Robin Waterfield
Jeremy Mark Wells
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of HU9801384D0 publication Critical patent/HU9801384D0/hu
Publication of HUP9801384A2 publication Critical patent/HUP9801384A2/hu
Publication of HUP9801384A3 publication Critical patent/HUP9801384A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány Clőstridiűm perfringens b-tőxin detőxifikált imműnőgénszármazékaira, valamint annak imműnőgén fragmenseire vőnatkőzik,amelyek közös jellemzője, hőgy a b-tőxin aminősav-szekvenciában, a vadtípűsú b-tőxinban elő nem főrdűló műtációt hőrdőznak. A találmánytárgyát képezik tővábbá, ilyen b-tőxinőkat kódőló gének, és ilyen b-tőxinőkat expresszáló expressziós rendszerek. Ezen felül a találmánytárgyáhőz tartőznak natív b-tőxint expresszáló bakteriális expressziósrendszerek. Végül a találmány tárgyát képezik Clőstridiűm perfringensb-tőxin genetikailag detőxifikált imműnőgén származé-kain alapűlóvakcinák, valamint az ilyen vakcinák előállítására szőlgáló eljárás. ŕ
HU9801384A 1997-06-20 1998-06-19 Clostridium perfringens vaccine HUP9801384A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201888 1997-06-20

Publications (3)

Publication Number Publication Date
HU9801384D0 HU9801384D0 (en) 1998-08-28
HUP9801384A2 true HUP9801384A2 (hu) 1999-03-29
HUP9801384A3 HUP9801384A3 (en) 2001-11-28

Family

ID=8228464

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801384A HUP9801384A3 (en) 1997-06-20 1998-06-19 Clostridium perfringens vaccine

Country Status (17)

Country Link
US (1) US6610300B1 (hu)
EP (1) EP0892054B1 (hu)
JP (1) JP4234232B2 (hu)
KR (1) KR19990007306A (hu)
CN (2) CN1215729A (hu)
AT (1) ATE346931T1 (hu)
AU (1) AU743498B2 (hu)
BR (1) BR9802361A (hu)
CA (1) CA2235445A1 (hu)
DE (1) DE69836520T2 (hu)
DK (1) DK0892054T3 (hu)
ES (1) ES2276448T3 (hu)
HU (1) HUP9801384A3 (hu)
NZ (1) NZ330749A (hu)
PT (1) PT892054E (hu)
TW (1) TWI221847B (hu)
ZA (1) ZA985393B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2768747B1 (fr) * 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2004046346A2 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
WO2007063075A1 (en) 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens
HUE027091T2 (hu) * 2006-03-30 2016-08-29 Zoetis Services Llc Eljárások és készítmények baromfi vakcinázására
CA2649426C (en) 2006-04-17 2014-04-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
MX2009005117A (es) * 2006-11-20 2009-05-27 Intervet Int Bv Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
CA3037889C (en) 2007-01-25 2022-09-13 Intrexon Actobiotics Nv Treatment of immune disease by mucosal delivery of antigens
RU2474587C2 (ru) * 2007-06-08 2013-02-10 Острэйлиан Паултри Срс Пти Лтд КЛОСТРИДИАЛЬНЫЙ ТОКСИН NetB
CA2699435A1 (en) * 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110882384B (zh) * 2019-12-17 2024-01-26 天康生物制药有限公司 猪流行性腹泻-猪梭菌性肠炎二联亚单位的口服疫苗及制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB958574A (en) * 1959-11-23 1964-05-21 Wellcome Found Clostridium perfringens ª‰-toxoid vaccines
SE7809880L (sv) * 1978-09-20 1980-03-21 Zemlyakova Valentina Porfiriev Vaccin for profylax och behandling av clostridiosis hos djur och fjederfe
US5817317A (en) * 1992-05-20 1998-10-06 The Secretary Of State For Defense Of Great Britian & Northern Ireland Clostridium perfringens vaccines
US5538851A (en) * 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
GB9522611D0 (en) 1995-11-03 1996-01-03 Brooks Holdings Ltd Improvements in and relating to a security closure for a door opening
GB9605222D0 (en) * 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines

Also Published As

Publication number Publication date
HU9801384D0 (en) 1998-08-28
DE69836520D1 (de) 2007-01-11
ZA985393B (en) 1999-02-17
JPH11103872A (ja) 1999-04-20
CN1215729A (zh) 1999-05-05
AU743498B2 (en) 2002-01-24
AU7308798A (en) 1998-12-24
ATE346931T1 (de) 2006-12-15
CA2235445A1 (en) 1998-12-20
JP4234232B2 (ja) 2009-03-04
DE69836520T2 (de) 2007-06-06
KR19990007306A (ko) 1999-01-25
ES2276448T3 (es) 2007-06-16
CN101914145A (zh) 2010-12-15
TWI221847B (en) 2004-10-11
US6610300B1 (en) 2003-08-26
EP0892054A1 (en) 1999-01-20
NZ330749A (en) 1999-10-28
BR9802361A (pt) 2000-01-11
EP0892054B1 (en) 2006-11-29
HUP9801384A3 (en) 2001-11-28
DK0892054T3 (da) 2007-04-02
PT892054E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
HUP9801384A2 (hu) Klostridium perfringens vakcina
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
BR9906927A (pt) Proteìnas de neisseria meningitidis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
MY119003A (en) Bacterial antigens and vaccine compositions
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
AU1463097A (en) Helicobacter pylori bacterioferritin
SG146662A1 (en) Method
AU5554301A (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
AUPQ347199A0 (en) Novel polypeptide fragments
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
AR004191A1 (es) Polipeptidos para inducir inmunidad protectora contra la tuberculosis, molecula de adn que los codifica, un vector de expresion, una celula huesped,una composicion farmaceutica, una vacuna, una proteina de fusion, un metodo para detectar la tuberculosis y kit de diagnostico.
WO1998046742A3 (de) Dictyocaulus viviparus antigen zur diagnose des lungenwurmbefalls und zur vakzinierung
AR003102A1 (es) Vacuna de env-glicoproteina para la proteccion de infeccion de htlv-i y ii

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: INTERVET INTERNATIONAL B.V., NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished